Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children and teenagers aged 3 to 17 years with a newly confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat), as classified by current international standards, OR adults aged 18 and over with a newly confirmed diagnosis of nasopharyngeal carcinoma that is linked to a virus called EBV, and is at stage II or III
• People aged 25 or under with stage II cancer or higher, OR people over 25 with stage III or IV cancer, based on standard cancer staging guidelines (AJCC, 8th edition)
• People whose cancer can be measured using MRI scans, according to standard research measurement rules
• People who have enough tumor tissue available (from a biopsy or surgery) to be sent for central laboratory review, including a specific protein test called PD-L1 staining
• People (or their legal guardians, if under 18) who are able to give written consent before the study begins
• People with a physical functioning level of at least 60 on standard activity scales used for their age group (confirm with trial site)

Who may not be able to join:

• People with newly diagnosed stage I nasopharyngeal carcinoma (any age), or stage II disease if they are over 25 years old
• People whose nasopharyngeal carcinoma has come back after a previous illness (recurrent cancer)
• People whose nasopharyngeal carcinoma is a second cancer, and who have already received chemotherapy or radiotherapy
• People who have previously had chemotherapy or radiotherapy for any reason
• People who currently have another active cancer
• People who have previously been treated with certain immune checkpoint or T-cell targeting drugs (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 medications)
• People who have received an experimental drug within the 30 days before joining this trial
• People who are currently enrolled in another clinical trial
• People who have previously had an organ transplant or a bone marrow transplant from a donor
• People with an active, known, or suspected autoimmune disease (however, certain conditions such as type 1 diabetes, thyroid conditions requiring only hormone replacement, or skin conditions not needing systemic treatment may still be eligible — confirm with trial site)
• People who have needed regular corticosteroid tablets or other immune-suppressing medications at significant doses within the 14 days before starting treatment (inhaled or skin-applied steroids at low doses may be acceptable — confirm with trial site)
• People with a current or past positive test result for hepatitis B or hepatitis C infection
• People with a known history of HIV or AIDS
• People whose blood, kidney, or liver test results fall below the minimum levels required by the trial (including low white blood cell counts, low platelets, low haemoglobin, poor kidney function, or abnormal liver markers — confirm with trial site for specific values)
• People with hearing loss greater than 20 decibels at a specific sound frequency (3 kHz) caused by an inner ear problem unrelated to the tumour
• People with a known allergy or sensitivity to platinum-based drugs or other medications used in this trial
• People with serious or uncontrolled heart conditions, including certain irregular heartbeat disorders within the past 12 months
• People who have received a live vaccine within 4 weeks before the first dose of the study drug
• People who are pregnant, as confirmed by a hormone test at screening
• People who are currently breastfeeding
• People who are held in an institution by order of a court or government authority
• People who are unwilling or unable to follow the procedures set out in the trial
• People who are considered mentally or legally unable to participate
• People with any other illness or medical condition that, in the treating doctor's judgement, could pose unacceptable risks or interfere with evaluating the study treatment

Important: Always verify eligibility with the trial site directly before applying.